Compare ALTO & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALTO | ADCT |
|---|---|---|
| Founded | 2003 | 2011 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 420.7M | 431.2M |
| IPO Year | 2005 | 2019 |
| Metric | ALTO | ADCT |
|---|---|---|
| Price | $5.15 | $1.14 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $7.75 |
| AVG Volume (30 Days) | 2.6M | ★ 3.1M |
| Earning Date | 05-07-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 119.51 | 30.86 |
| EPS | ★ 0.05 | N/A |
| Revenue | ★ $917,927,000.00 | $81,357,000.00 |
| Revenue This Year | $6.66 | N/A |
| Revenue Next Year | $0.43 | $66.49 |
| P/E Ratio | $104.40 | ★ N/A |
| Revenue Growth | N/A | ★ 14.85 |
| 52 Week Low | $0.92 | $0.78 |
| 52 Week High | $6.00 | $4.98 |
| Indicator | ALTO | ADCT |
|---|---|---|
| Relative Strength Index (RSI) | 48.13 | 22.25 |
| Support Level | $4.27 | $0.78 |
| Resistance Level | $5.98 | $4.77 |
| Average True Range (ATR) | 0.36 | 0.16 |
| MACD | -0.06 | 0.00 |
| Stochastic Oscillator | 27.39 | 15.43 |
Alto Ingredients Inc is a producer and distributor of specialty alcohols, renewable fuels and essential ingredients in the United States. The company serves five markets: Health, Home and Beauty, Food and Beverage, Essential Ingredients, and Renewable Fuels. Its customers include food and beverage companies and consumer products manufacturers and distributors. The company operates under three segments: Marketing and distribution, Pekin Campus production, and Western production.
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Additionally, the company's development pipeline comprises LOTIS-2, LOTIS-5, LOTIS-7, and ADCT-241, being developed as potential therapies for different cancer diseases. Geographically, the firm generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).